Patents Assigned to Oncogen
  • Patent number: 6194200
    Abstract: Expression cassettes for enhanced expression and production of a polypeptide of interest in prokaryotic cells are provided. The expression cassettes provide for production of the polypeptide of interest so that such polypeptide can either be secreted from the host cell in an active conformation or conveniently processed and renatured to a functional state. Preferably, the polypeptide of interest is expressed as a fusion protein, particularly fused to a leader sequence from a highly expressed bacterial or bacteriophage gene. The polypeptide of interest may subsequently be cleaved from the leader sequence and refolded, or used as a fusion protein.
    Type: Grant
    Filed: December 18, 1992
    Date of Patent: February 27, 2001
    Assignee: Oncogen
    Inventors: Timothy M. Rose, A. Gregory Bruce
  • Patent number: 5976793
    Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene-of-interest. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell. Additionally, this invention provides a method for determining whether a molecule known to be a modulator of protein biosynthesis is capable of transcriptionally modulating expression of a gene-of-interest.
    Type: Grant
    Filed: July 18, 1996
    Date of Patent: November 2, 1999
    Assignee: Oncogene Science, Inc.
    Inventors: J. Gordon Foulkes, Franz Leichtfried, Christian Pieler, John R. Stephenson
  • Patent number: 5863733
    Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene-of-interest. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell. Additionally, this invention provides a method for determining whether a molecule known to be a modulator of protein biosynthesis is capable of transcriptionally modulating expression of a gene-of-interest.
    Type: Grant
    Filed: January 6, 1997
    Date of Patent: January 26, 1999
    Assignee: Oncogene Science, Inc.
    Inventors: J. Gordon Foulkes, Franz Leichtfried, Christian Pieler, John R. Stephenson
  • Patent number: 5846720
    Abstract: The invention provided for a method of transcriptionally modulating the expression of a gene encoding a protein of interest associated with treatment of one or more symptoms of a cardiovascular disease. Further provided is a method of determining whether a molecule not previously known to be a modulator of protein biosynthesis is capable of directly and specifically transcriptionally modulating the expression of a gene encoding a protein of interest associated with treatment of one or more symptoms of a cardiovascular disease. Screening methods, including methods of essentially simultaneously screening molecules to determine whether the molecules are capable of directly and specifically transcriptionally modulating one or more genes encoding proteins of interest associated with treatment of one or more symptoms of a cardiovascular disease, are also provided.
    Type: Grant
    Filed: August 15, 1996
    Date of Patent: December 8, 1998
    Assignee: Oncogene Science, Inc.
    Inventors: J. Gordon Foulkes, Franz E. Liechtfried, Christian Pieler, John R. Stephenson, Casey C. Case
  • Patent number: 5824297
    Abstract: The present invention provides a method for inhibiting cytotoxic poisoning of normal cells in a subject which comprises administering to the subject an amount of a Transforming Growth Factor Beta effective to slow the growth of normal cells and thereby inhibit the cytotoxic poisoning of the normal cells in the subject. Typically, administration is topical and initiated prior to anti-neoplastic therapy such as radiation treatment or chemotherapy. The invention is particularly suited for pediatric patients.
    Type: Grant
    Filed: September 1, 1993
    Date of Patent: October 20, 1998
    Assignee: Oncogene Science, Inc.
    Inventors: Kenneth K. Iwata, J. Gordon Foulkes, Peter Ten Dijke, John D. Haley
  • Patent number: 5817625
    Abstract: The present invention provides methods of preventing oral mucositis in a subject susceptible to mucositis which comprises administering to the subject a prophylactically effective amount of Transforming Growth Factor Beta. Typically, administration is topical and initiated prior to anti-neoplastic therapy such as radiation treatment or chemotherapy. The invention is particularly suited for pediatric patients.
    Type: Grant
    Filed: January 9, 1995
    Date of Patent: October 6, 1998
    Assignee: Oncogene Science, Inc.
    Inventor: John Douglas Haley
  • Patent number: 5786456
    Abstract: A new B-cell receptor, Bp50, a 50 kilodalton polypeptide, that functions in B-cell proliferation is described. Ligands such as lymphokines, antibody molecules or the Fv fragments of antibody molecules that bind to Bp50 and augment the proliferation of activated B-cells can be used to regulate B-cell proliferation or differentiation.
    Type: Grant
    Filed: September 20, 1993
    Date of Patent: July 28, 1998
    Assignee: Oncogen
    Inventors: Jeffrey A. Ledbetter, Edward A. Clark
  • Patent number: 5776502
    Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene of interest, the expression of which is associated with a defined physiological or pathological effect within a multicellular organism. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) specifically transcriptionally modulate expression of the gene of interest, and (c) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell, the binding of a ligand to which ligand binding domain is normally associated with the defined physiological or pathological effect.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: July 7, 1998
    Assignee: Oncogene Science, Inc.
    Inventors: J. Gordon Foulkes, Robert Franco, Franz Leichtfried, Christian Pieler, John R. Stephenson
  • Patent number: 5766588
    Abstract: The present invention relates to methods which utilize anti-idiotypic antibodies, or fragments thereof, for tumor immunotherapy or immunoprophylaxis. Monoclonal anti-idiotypic antibodies which recognize an idiotype present on a second antibody or on a T lymphocyte or on an immune suppressor factor which is directed against a defined tumor antigen, can be used for immunization against a tumor, for immune anti-tumor activation or inhibition of suppression, or for in vitro activation of lymphocytes to be used in adoptive immunotherapy. The anti-idiotypic antibodies, or fragments thereof, can also be used to monitor anti-antibody induction in patients undergoing passive immunization to a tumor antigen by administration of anti-tumor antibody. In another embodiment, administration of T lymphocytes which express an idiotype directed against a defined tumor antigen can be used to transfer delayed-type hypersensitivity to the tumor.
    Type: Grant
    Filed: September 22, 1995
    Date of Patent: June 16, 1998
    Assignee: Oncogen
    Inventors: Ingegerd Hellstrom, Karl Erik Hellstrom, Victor K. Lee
  • Patent number: 5665543
    Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene-of-interest. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell. Additionally, this invention provides a method for determining whether a molecule known to be a modulator of protein biosynthesis is capable of transcriptionally modulating expression of a gene-of-interest.
    Type: Grant
    Filed: June 28, 1994
    Date of Patent: September 9, 1997
    Assignee: Oncogene Science, Inc.
    Inventors: J. Gordon Foulkes, Franz Leichtfried, Christian Pieler, John R. Stephenson, Robert Franco
  • Patent number: 5646002
    Abstract: A method for treating serum samples to remove sialic acid from ligands to expose binding sites to enhance immunological binding, for use in assays and to generate novel anti-ligands is described. The method includes treatment of serum using neuraminidase.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: July 8, 1997
    Assignee: Oncogen Limited Partnership
    Inventors: Peter S. Linsley, Vincent Ochs, Diane Horn, Joseph P. Brown
  • Patent number: 5645835
    Abstract: The present invention relates to methods of providing a targeted, amplified antitumor immune response using antibody-based fusion proteins. More specifically, the invention relates to the use of antibody-based fusion proteins comprising an immunoglobulin portion capable of binding to a tumor antigen linked to a biologically active lymphokine. The immunoglobulin portion targets the fusion protein to the site of the tumor cells and the lymphokine portion stimulates the proliferation of immune T cells at the site of the tumor cells, thereby amplifying the anti-tumor immune response. In preferred embodiments of the invention, the immunoglobulin portion of the fusion protein is derived from the L6 monoclonal antibody and/or the lymphokine is interleukin-2.
    Type: Grant
    Filed: May 23, 1994
    Date of Patent: July 8, 1997
    Assignee: Oncogen
    Inventors: Henry Perry Fell, Jr., Margit Ann Gayle
  • Patent number: 5635489
    Abstract: The present invention provides methods of preventing oral mucositis in a subject susceptible to mucositis which comprises administering to the subject a prophylactically effective amount of TGF-.beta.3. Typically, administration is topical and initiated prior to anti-neoplastic therapy such as radiation treatment or chemotherapy. The invention is particularly suited for pediatric patients.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: June 3, 1997
    Assignee: Oncogene Science, Inc.
    Inventor: John D. Haley
  • Patent number: 5618715
    Abstract: Novel compositions comprising Oncostatin M and congeners thereof, as well as methods for their preparation and methods for their use are provided. The compositions may be prepared by isolation from natural sources, or by recombinant means in either prokaryotic or eukaryotic host cells. In addition, the DNA and polypeptide sequences for Oncostatin M are disclosed. The compositions find use in modulating growth of cells, in particular inhibition of tumor cell proliferation, and stimulation of normal cell growth, especially cells involved in hematopoiesis. Cell growth inhibition compositions may additionally include an adjunctive agent comprising at least one of a transforming growth factor, tumor necrosis factor, or an interferon. Receptors having high affinity for Oncostatin M may additionally be used to screen polypeptides for Oncostatin M-like activity. Methods for use of antibodies to the compositions and probes specific for Oncostatin M mRNA as a means for detecting tumor cells are also provided.
    Type: Grant
    Filed: June 10, 1993
    Date of Patent: April 8, 1997
    Assignee: Oncogen Limited Partnership
    Inventors: Mohammed Shoyab, Joyce M. Zarling, Hans Marquardt, Marcia B. Hanson, Najma Malik, Peter S. Linsley, Timothy M. Rose, Anthony F. Purchio
  • Patent number: 5614610
    Abstract: The present invention relates to methods which utilize anti-idiotypic antibodies, or fragments thereof, for tumor immunotherapy or immunoprophylaxis. Monoclonal anti-idiotypic antibodies which recognize an idiotype present on a second antibody or on a T lymphocyte or on an immune suppressor factor which is directed against a defined tumor antigen, can be used for immunization against a tumor, for immune anti-tumor activation or inhibition of suppression, or for in vitro activation of lymphocytes to be used in adoptive immunotherapy. The anti-idiotypic antibodies, or fragments thereof, can also be used to monitor anti-antibody induction in patients undergoing passive immunization to a tumor antigen by administration of anti-tumor antibody. In another embodiment, administration of T lymphocytes which express an idiotype directed against a defined tumor antigen can be used to transfer delayed-type hypersensitivity to the tumor.
    Type: Grant
    Filed: July 28, 1988
    Date of Patent: March 25, 1997
    Assignee: Oncogen
    Inventors: Ingegerd Hellstrom, Karl E. Hellstrom, Maria S. Kahn, Donna F. Beaton
  • Patent number: 5604107
    Abstract: This invention relates to a substantially purified p100 which is a human neu related protein having a molecular weight in the range from about 97,000 daltons to about 115,000 daltons which corresponds substantially to the extracellular domain of the human neu gene product, said protein being detectable in a biological fluid.In another embodiment this invention relates to assays for detecting this protein.Finally, this invention also concerns monoclonal antibodies which are capable of binding to p100.
    Type: Grant
    Filed: March 30, 1994
    Date of Patent: February 18, 1997
    Assignee: Oncogene Science, Inc.
    Inventors: Walter P. Carney, Sara J. McKenzie, Robert A. Weinberg
  • Patent number: 5597578
    Abstract: Antiproliferative compositions are provided which are capable of sustained release of an antiproliferative agent, particularly a TGF-.beta., at a site proximal to a target cell. The compositions are effective in inhibiting proliferation of the target cell, particularly when used in combination with a vasoconstrictive agent.
    Type: Grant
    Filed: April 28, 1994
    Date of Patent: January 28, 1997
    Assignees: Oncogen, Matrix Pharmaceuticals
    Inventors: Dennis M. Brown, Edward Luck, Daniel R. Twardzik, Anthony F. Purchio
  • Patent number: 5580722
    Abstract: The invention provided for a method of directly and specifically transcriptionally modulating the expression of a gene encoding a protein of interest associated with treatment of one or more symptoms of a cardiovascular disease such as atherosclerosis, restenosis or hypertension.Further provided is a method of determining whether a molecule not previously known to be a modulator of protein biosynthesis is capable of directly and specifically transcriptionally modulating the expression of a gene encoding a protein of interest associated with treatment of one or more symptoms of a cardiovascular disease.Lastly, the invention provides a method of directly and specifically transcriptionally modulating in a human being the expression of a gene encoding a protein of interest associated with treatment of one or more symptoms of a cardiovascular disease, thus ameliorating the disease.
    Type: Grant
    Filed: February 7, 1992
    Date of Patent: December 3, 1996
    Assignee: Oncogene Science, Inc.
    Inventors: J. Gordon Foulkes, Franz E. Liechtfried, Christian Pieler, John R. Stephenson, Casey C. Case
  • Patent number: 5545548
    Abstract: Thermally stable cytosine deaminase (CDase), and the gene coding therefor, is disclosed as well as methods of isolating, purifying, and recombinantly producing the same. The thermally stable CDase can be isolated from Saccharomyces cerevisiae. The yeast isolated enzyme has a molecular weight of approximately 32 kDa, as determined by gel filtration chromatography, and is composed of two subunits, each with a molecular weight of about 17 kDa. Thermally stable yeast CDase so purified shows no significant sequence homology with other known sequenced proteins.
    Type: Grant
    Filed: June 20, 1994
    Date of Patent: August 13, 1996
    Assignee: Oncogen
    Inventors: Peter D. Senter, Peter C. Su, Hans Marquardt, Martha S. Hayden, Peter Linsley
  • Patent number: 5491088
    Abstract: The present invention relates to novel antibodies reactive with human carcinoma cells. More particularly, the antibodies of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; and a F(ab').sub.2 fragment of BR96. These antibodies are reactive with a cell membrane antigen on the surface of human carcinomas. The antibodies display a high degree of selectivity for carcinoma cells and possess the ability to mediate ADCC and CDC activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.
    Type: Grant
    Filed: May 5, 1993
    Date of Patent: February 13, 1996
    Assignee: Oncogen Limited Partnership
    Inventors: Ingegerd Hellstrom, Karl E. Hellstrom, Kim F. Bruce, George J. Schreiber